PI3Kδ/γ Inhibitor Duvelisib Modulates Inflammatory Profile in Severe COVID-19 Patients: Results from a Randomized Placebo-Controlled Phase 2 Study

Bibliographic Details
Title:	PI3Kδ/γ Inhibitor Duvelisib Modulates Inflammatory Profile in Severe COVID-19 Patients: Results from a Randomized Placebo-Controlled Phase 2 Study
Authors:	Zhang, Hanwen, Wang, Shuhua ^, Rupji, Manali ^, Wu, Chenxi ^, Chandrasekaran, Sanjay ^, Funk, Christopher R., King, Patrick J. ^, Kollipara, Saketh ^, Rao, Ishani ^, Ayanru, Esohe ^, Duffy, Julia ^, Kaplow, Roberta ^, Abousaud, Aseala ^, Mehta, Aneesh ^, Roback, John D. ^, Kalman, Daniel ^, Lyon, G. Marshall, III ^, Caridi-Scheible, Mark ^, Bisson, Gregory ^, Liu, Yuan ^, Coma, Silvia ^, Pachter, Jonathan A. ^, Giver, Cynthia R., Waller, Edmund K.
Source:	In Blood 15 November 2022 140 Supplement 1:11187-11189
Database:	ScienceDirect